3-[(1-Naphthyloxy)methyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-[(1-Naphthyloxy)methyl]benzoic acid
• 英文别名: 3-(naphthalen-1-yloxymethyl)benzoic acid
• 化学式: C₁₈H₁₄O₃
• mdl: MFCD02253722
• 分子量: 278.307
• InChiKey: DNEWINHTWSXKJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2020198537A1

  公开（公告）日：2020-10-01

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

  提供了一种通过接触MRGPR X4或向需要的受试者施用具有以下结构的化合物的有效量，从而对MRGPR X4进行调节，或更具体地用于治疗依赖于MRGPR X4的疾病，其中该结构为Formula (I): (I)或其药学上可接受的异构体、拉克酸盐、水合物、溶剂合物、同位素或盐，其中n、x、A、Q1、Q2、Z、R、R1、R2、R3、R4和R5的定义如本文所述。还提供了含有这些化合物的药物组合物，以及化合物本身。
• MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
  申请人：Escient Pharmaceuticals, Inc.

  公开号：US20210032213A1

  公开（公告）日：2021-02-04

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I). or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q 1 , Q 2 , Z, R, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.